Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. [electronic resource]
Producer: 20190806Description: 2578-2586 p. digitalISSN:- 1097-0215
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Breast Neoplasms -- drug therapy
- Clinical Trials, Phase III as Topic
- Deoxycytidine -- analogs & derivatives
- Disease-Free Survival
- Docetaxel -- therapeutic use
- Female
- Gene Expression Profiling -- methods
- Humans
- Kaplan-Meier Estimate
- Nestin -- metabolism
- Phosphoric Monoester Hydrolases -- metabolism
- Prognosis
- Prospective Studies
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.